General and administrative expense also fell 16.7% to $6.5 million, thanks largely …
NWI7d
An ongoing trial with a lot more patients from this well-defined group is expected to wrap up early next year. Celldex Therapeutics stock has fallen about 31% this …
Celldex expects that this cash plus anticipated proceeds from the future sales of its common stock under the agreement with Cantor will be enough to fund working capital requirements and planned operations through 2018. However, the …
H.C. Wainwright maintained it with “Buy” rating and $6 target in Tuesday, March 8 report. The stock of Celldex
A year ago, they were trading at $4.52. This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CLDX at https://www.zacks.com/ap/CLDX
However, if the CLDX shares go below $2.34 then it would indicate a much ... Manufacturers Life Communication The accumulated 37,266 shares or 0% of the …
However, this guidance assumes that we elect to pay the Kolltan contingent milestones, if any, in stock rather than …